Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1996 1
1997 1
1998 3
2000 4
2001 10
2002 7
2003 7
2004 18
2005 21
2006 32
2007 38
2008 43
2009 37
2010 49
2011 46
2012 44
2013 47
2014 39
2015 58
2016 56
2017 56
2018 54
2019 60
2020 62
2021 49
2022 59
2023 11
Text availability
Article attribute
Article type
Publication date

Search Results

766 results
Results by year
Filters applied: . Clear all
Page 1
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. Shen B, et al. Among authors: vermeire s. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):69-95. doi: 10.1016/S2468-1253(21)00214-4. Epub 2021 Nov 10. Lancet Gastroenterol Hepatol. 2022. PMID: 34774224 Review.
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Sandborn WJ, et al. Among authors: vermeire s. N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910. N Engl J Med. 2017. PMID: 28467869 Free article. Clinical Trial.
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. Salas A, et al. Among authors: vermeire s. Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):323-337. doi: 10.1038/s41575-020-0273-0. Epub 2020 Mar 19. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32203403 Review.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. Among authors: vermeire s. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
Geldof J, Iqbal N, LeBlanc JF, Anandabaskaran S, Sawyer R, Buskens C, Bemelman W, Gecse K, Lundby L, Lightner AL, Danese S, Spinelli A, Carvello M, Faiz O, Warusavitarne J, Lung P, De Looze D, D'Hoore A, Vermeire S, Hart A, Tozer P. Geldof J, et al. Among authors: vermeire s. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):576-584. doi: 10.1016/S2468-1253(22)00007-3. Epub 2022 Mar 21. Lancet Gastroenterol Hepatol. 2022. PMID: 35325623 Review.
Big data in IBD: big progress for clinical practice.
Seyed Tabib NS, Madgwick M, Sudhakar P, Verstockt B, Korcsmaros T, Vermeire S. Seyed Tabib NS, et al. Among authors: vermeire s. Gut. 2020 Aug;69(8):1520-1532. doi: 10.1136/gutjnl-2019-320065. Epub 2020 Feb 28. Gut. 2020. PMID: 32111636 Free PMC article. Review.
New treatment options for inflammatory bowel diseases.
Verstockt B, Ferrante M, Vermeire S, Van Assche G. Verstockt B, et al. Among authors: vermeire s. J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. J Gastroenterol. 2018. PMID: 29556726 Free PMC article. Review.
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Papamichael K, et al. Among authors: vermeire s. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5. Lancet Gastroenterol Hepatol. 2022. PMID: 35026171 Review.
Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. Loftus EV Jr, et al. Among authors: vermeire s. Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365. doi: 10.1111/apt.16060. Epub 2020 Sep 2. Aliment Pharmacol Ther. 2020. PMID: 32876349 Free PMC article. Clinical Trial.
766 results